Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.31 |
| ▸ | RORB | Q92753 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002858 | 0.90 | CA12 (0.37) | MAPTKMT2APKMALDH1A1PDE4B | |
| SCHEMBL6000928 | 0.85 | RAB9A (0.39) | MAPTRXFP1NPSR1KMT2APKM | |
| SCHEMBL5068850 | 0.80 | CA12 (0.44) | MAPTKMT2APKMALDH1A1PDE4B | |
| SCHEMBL6000924 | 0.75 | RAB9A (0.42) | MAPTRXFP1KMT2APKMSMN1; SMN2 | |
| SCHEMBL642545 | 0.70 | CYP3A4 (0.50) | MAPTKMT2APKMALDH1A1 | |
| SCHEMBL20094718 | 0.66 | RAB9A (0.48) | MAPTRXFP1KMT2APKMALDH1A1 | |
| SCHEMBL20554137 | 0.66 | CYP3A4 (0.51) | MAPTKMT2APKM | |
| SCHEMBL20031462 | 0.66 | ALDH1A1 (0.46) | MAPTRXFP1NPSR1KMT2APKM | |
| SCHEMBL19900251 | 0.65 | CYP2C9 (0.42) | MAPTKMT2APKMALDH1A1SMN1; SMN2 | |
| SCHEMBL5069164 | 0.65 | CA12 (0.58) | KMT2APKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | MAPT 4195/4885RXFP1 426/4885NPSR1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.